← Back to Search

Virus Therapy

mRNA-1011.1 + mRNA-1011.2 + mRNA-1012.1 for Flu

Phase 1 & 2
Waitlist Available
Research Sponsored by ModernaTX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) to day 29
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing three new flu vaccines in healthy adults to see how safe they are and how well they help the body fight the flu using mRNA technology.

Eligible Conditions
  • Flu

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) to day 29
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) to day 29 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Percentage of Participants With Seroconversion, as Measured by HAI Assay

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

7Treatment groups
Experimental Treatment
Active Control
Group I: mRNA-1012.1 Dose Level BExperimental Treatment1 Intervention
Participants will receive mRNA-1012.1 at dose level B by IM injection on Day 1.
Group II: mRNA-1012.1 Dose Level AExperimental Treatment1 Intervention
Participants will receive mRNA-1012.1 at dose level A by IM injection on Day 1.
Group III: mRNA-1011.2Experimental Treatment1 Intervention
Participants will receive mRNA-1011.2 by IM injection on Day 1.
Group IV: mRNA-1011.1Experimental Treatment1 Intervention
Participants will receive mRNA-1011.1 by intramuscular (IM) injection on Day 1.
Group V: mRNA-1010.3Active Control1 Intervention
Participants will receive mRNA-1010.3 by IM injection on Day 1.
Group VI: mRNA-1010Active Control1 Intervention
Participants will receive mRNA-1010 by IM injection on Day 1.
Group VII: mRNA-1010.2Active Control1 Intervention
Participants will receive mRNA-1010.2 by IM injection on Day 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
mRNA-1012.1
2023
Completed Phase 2
~700
mRNA-1011.1
2023
Completed Phase 2
~700
mRNA-1011.2
2023
Completed Phase 2
~700

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

ModernaTX, Inc.Lead Sponsor
120 Previous Clinical Trials
61,587,509 Total Patients Enrolled

Media Library

mRNA-1011.1 (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05827068 — Phase 1 & 2
Flu Research Study Groups: mRNA-1011.2, mRNA-1012.1 Dose Level A, mRNA-1012.1 Dose Level B, mRNA-1010.3, mRNA-1010, mRNA-1010.2, mRNA-1011.1
Flu Clinical Trial 2023: mRNA-1011.1 Highlights & Side Effects. Trial Name: NCT05827068 — Phase 1 & 2
mRNA-1011.1 (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05827068 — Phase 1 & 2
~262 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top